Infections caused by anaerobes, Streptococci, Staphylococci or pneumococci.

Clindamycin appears to inhibit protein synthesis in susceptible organisms by binding to 50S ribosomal subunits; the primary effect is inhibition of peptide bond formation. Clindamycin may be bacteriostatic or bactericidal in action, depending on the concentration of the drug attained at the site of infection and the susceptibility of the infecting organism.

Approximately 90% of an oral dose of clindamycin hydrochloride is rapidly absorbed from the GI tract. Clindamycin is distributed into many body tissues and fluids including saliva, ascites fluid, pleural fluid, synovial fluid, bone, and bile. However, even in the presence of inflamed meninges, only small amounts of the drug diffuse into CSF. Clindamycin is partially metabolized to bioactive and inactive metabolites. Within 24 hours, approximately 10% of an oral dose of clindamycin is excreted in urine and 3.6% is excreted in feces as active drug and metabolites; the remainder is excreted as inactive metabolites. The serum half-life of clindamycin is 2–3 hours in adults and children with normal renal function.

Hypersensitivity, diarrhea states.

B

Probably safe; it has the possible to depress bowel normal flora, to interfere culture interpretation, or to induce allergy reaction in infant.

Diarrhea, Pseudomembranous colitis, hypersensitivity reactions, agranulocytosis, thrombocytopenia.

Adults: 150-300 mg Q6H PO, severe infection: 450 mg Q6H PO; Children: 8-16 mg/kg/day in 4 divided dose up to 20 mg/kg/day PO